文献速递胸部肿瘤

纳武利尤单抗联合厄洛替尼治疗EGFR突变晚期NSCLC的I期研究

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.
PubMed 文献 · J Thorac Oncol · 2018-05-23

这项I期研究评估纳武利尤单抗联合厄洛替尼治疗EGFR突变晚期NSCLC的安全性和耐受性。20例TKI经治和1例TKI初治患者接受联合治疗,TKI经治人群客观缓解率15%,24周无进展生存率48%,缓解持久,联合方案可耐受。

要点

  • TKI经治EGFR突变NSCLC中,纳武利尤单抗联合厄洛替尼客观缓解率15%,24周PFS率48%
  • 治疗相关3级毒性5例,无4级及以上毒性,联合方案可耐受
  • TKI经治患者中位缓解持续时间达13.8至38.2个月,显示持久缓解

核心结论

  • 纳武利尤单抗联合厄洛替尼在EGFR突变TKI经治NSCLC中可耐受,并观察到持久缓解。

研究设计与样本

  • I期研究,纳入20例TKI经治和1例TKI初治的EGFR突变晚期NSCLC患者。
  • 治疗方案为纳武利尤单抗3 mg/kg每2周联合厄洛替尼150 mg/d,直至疾病进展或不可耐受毒性。
  • 主要终点为安全性和耐受性。

主要发现

  • 治疗相关3级毒性发生于5例患者(肝酶升高2例、腹泻2例、体重下降1例),无4级及以上毒性。
  • TKI经治人群客观缓解率为15%(3/20,含1例完全缓解),24周无进展生存率为48%。
  • TKI经治患者中3例缓解持续时间分别为13.8、17.6和38.2个月(研究者记录),另1例非传统免疫相关缓解持续12.5个月。
  • TKI初治患者携带EGFR L858R和S768I复合突变,最终达到完全缓解,持续缓解超过5年(研究者记录)。

临床怎么用

  • 对于EGFR突变TKI经治的晚期NSCLC,纳武利尤单抗联合厄洛替尼可作为可耐受的治疗选择,但需关注肝酶升高和腹泻等3级毒性。
  • 联合方案的客观缓解率有限(15%),临床应用需权衡获益与免疫相关不良反应风险。

局限性

  • 主要终点为安全性,疗效数据为次要观察,缺乏随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This phase I study evaluated nivolumab combined with erlotinib in patients with advanced EGFR-mutant NSCLC. METHODS: Patients with advanced EGFR-mutant NSCLC who were EGFR tyrosine kinase inhibitor (TKI)-naive or TKI-treated but had not received chemotherapy were treated with nivolumab 3 mg/kg every 2 weeks and erlotinib 150 mg/d until disease progression or unacceptable toxicity. The primary objective was safety and tolerability. RESULTS: Twenty patients with TKI-treated and one with TKI-naive EGFR-mutant NSCLC were treated with nivolumab plus erlotinib. Treatment-related grade 3 toxicities occurred in five patients (liver enzyme elevations, n = 2; diarrhea, n = 2; weight loss, n = 1), with no grade ≥4 toxicities. In the TKI-treated population, the objective response rate was 15% (3 of 20, including one complete response), and the 24-week progression-free survival rate was 48%. Responses lasted 13.8, 17.6, and 38.2 months per investigator records. A fourth patient had a nonconventional immune-related response lasting 12.5 months. Among these four patients, two were never-smokers and one each had 35- and <1-pack-year histories. Post-EGFR TKI pre-trial tumor biopsy specimens from these patients detected EGFR T790M mutations in two patients and MNNG HOS Transforming gene (MET) amplification in a third; two patients each had primary EGFR exon 19 deletions or L858R mutations. The TKI-naive patient, who had compound EGFR mutations (L858R and S768I) and ultimately achieved a complete response, had an ongoing response lasting more than 5 years based on investigator records. CONCLUSIONS: Nivolumab plus erlotinib was tolerable, with durable responses in patients with EGFR-mutant, TKI-treated NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Gettinger S, Hellmann MD, Chow LQM, et al. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. J Thorac Oncol. 2018. PMID: 29802888. doi:10.1016/j.jtho.2018.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。